We are live on ! Find out more
TOVX icon

Theriva Biologics
TOVX

10 hedge funds and large institutions have $60.3K invested in Theriva Biologics in 2024 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

35.22% less ownership

Funds ownership: 36.46% → 1.24% (-35%)

44% less funds holding

Funds holding: 18 → 10 (-8)

78% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 9

91% less capital invested

Capital invested by funds: $679K → $60.3K (-$618K)

Holders
10
Holders Change
-8
Holders Change %
-44.44%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
2
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citigroup
Citigroup
New York
+$11.3K
2
TRCT
Tower Research Capital (TRC)
New York
+$1.07K
3
Bank of America
Bank of America
North Carolina
+$16

Top Sellers

Rank Fund Capital Flow
1
HCM
Heights Capital Management
California
-$196K
2
AFM
Anson Funds Management
Texas
-$192K
3
AC
Armistice Capital
New York
-$138K
4
MP
MSD Partners
New York
-$37.7K
5
Morgan Stanley
Morgan Stanley
New York
-$27.9K

TOVX Hedge Fund Activity: Q4 2024 in Review

10 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q4 2024, worth a combined $60.3K — down 91% from $679K a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of TOVX and 2 opened new positions — a net loss of 7 holders — while 2 trimmed existing stakes and 2 added.

The largest buyer was Citigroup, opening a new position worth an estimated $11.3K. The largest seller was Heights Capital Management, exiting entirely with an estimated $196K sold.

  • 10 institutional investors held Theriva Biologics (TOVX) as of Q4 2024, down from 18 in Q3 2024.
  • Funds reported $60.3K of Theriva Biologics stock for Q4 2024, down 91% quarter-over-quarter.
  • 2 funds opened new Theriva Biologics positions in Q4 2024 and 9 closed out, a net change of -7 holders.
  • The largest Theriva Biologics buyer in Q4 2024 was Citigroup, an estimated $11.3K added.
  • The largest Theriva Biologics seller in Q4 2024 was Heights Capital Management, an estimated $196K sold.

Based on aggregated 13F filings for Q4 2024.